迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02493 迈威生物-B

未开盘 05-13 16:08:10

25.140

-0.880

-3.38%

最高26.140	最低25.100	成交量73.54万
今开26.020	昨收26.020	日振幅4.00%
总市值112.38亿	流通市值11.85亿	总股本4.47亿
成交额1,876万	换手率1.56%	流通股本4,713万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":25.14,"timestamp":1778659690692,"preClose":26.02,"halted":0,"volume":735400,"delay":0,"changeRate":-0.03382013835511141,"floatShares":47130200,"shares":447000000,"eps":0,"marketStatus":"未开盘","change":-0.88,"latestTime":"05-13 16:08:10","open":26.02,"high":26.14,"low":25.1,"amount":18756724,"amplitude":0.039969,"askPrice":25.16,"askSize":800,"bidPrice":25.14,"bidSize":6800,"shortable":0,"etf":0,"ttmEps":-2.331,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778722200000},"marketStatusCode":0,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":26.02,"openAndCloseTimeList":[[1778635800000,1778644800000],[1778648400000,1778659200000]],"volumeRatio":0.491966,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":35.2,"timestamp":1778655600000,"preClose":35.98,"halted":0,"volume":6813800,"delay":0,"premium":"-38.10"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2634409827","title":"5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409827?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488118,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日迈威生物涨5.80%，收盘报37.2元，换手率6.99%，成交量14.28万手，成交额5.18亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.7862，较上一交易日下跌2.29%，近一年上涨13.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000808.SH","02493","BK1161","163118","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634472914","title":"港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2634472914","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634472914?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:57","pubTimestamp":1778479078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B午后涨近5%，截至发稿，涨3.54%，报27.52港元，成交额3326.31万港元。消息面上，迈威生物宣布，其自主研发的抗体创新药9MW5211的临床试验申请正式获得美国食品药品监督管理局的许可，可针对炎症性肠病开展临床研究。其用于IBD和多发性硬化等多个适应症的临床试验申请已获国家药品监督管理局受理。9MW5211在其靶点上是全球首款进入临床阶段的候选药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","BK1161","VXUS","BK4585","BK1574","688062","BK4588","LABU","BK0239","159992","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432532","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432532","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432532?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:15","pubTimestamp":1778235339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，，9MW5211注射液用于炎症性肠病适应症的临床试验申请正式获得FDA许可，同时，其用于IBD和多发性硬化等多个适应症的临床试验申请已获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","LABU","02493","BK0239","BK4585","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195321528","title":"迈威生物-B发布2026年4月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1195321528","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195321528?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:55","pubTimestamp":1778154938,"startTime":"0","endTime":"0","summary":"2026年5月7日，迈威生物-B（股票代码：02493）公布截至2026年4月30日止的证券变动月报。报告显示，公司H股为47,130,200股，A股为399,600,000股，注册股本合计人民币446,730,200元，各类股份在4月均未出现新增发行、回购或注销情形，股本总数维持不变。公司H股于2026年4月28日在香港联交所主板正式上市，上月底结存指上市日在册数据。\n公司公告称，已满足相关上市规则的公众持股量及其他合规要求。公司确认遵守香港联交所《上市规则》等适用法律法规的规定。公告由联席公司秘书王鹤飞女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633131510","title":"迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131510?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:09","pubTimestamp":1778076591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，为进一步优化债务结构，拓宽公司融资渠道，降低公司财务成本，根据公司战略发展规划及资金需求，公司拟向中国银行间市场交易商协会申请注册发行规模不超过10亿元(含10亿元)的定向债务融资工具。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","02493","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631702570","title":"迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631702570","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631702570?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:31","pubTimestamp":1777519860,"startTime":"0","endTime":"0","summary":"　　迈威生物-B最高涨超23%，触及31.46港元，创上市新高。截至发稿，涨7.22%，报27.32港元，成交额1.84亿港元。自成立以来，公司已推动4款产品获批上市，实现4款创新品种的对外授权。　　值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-30/doc-inhwfyeh7154434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1161","688062","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631357717","title":"港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2631357717","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631357717?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:48","pubTimestamp":1777517308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B最高涨超23%，触及31.46港元创上市新高。值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"54a3c0ad0e347d9e6f95c7a6e00c2a09","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02493","688062","VXUS","BK4585","BK4588","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184728154","title":"异动解读 | 迈威生物-B盘中大涨5.02%，一季报营收激增亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1184728154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184728154?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:43","pubTimestamp":1777513394,"startTime":"0","endTime":"0","summary":"迈威生物-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，迈威生物近日发布了2026年第一季度财报，显示公司主营收入达到1.28亿元，同比大幅上升184.89%；同时，归母净利润为-2.42亿元，亏损同比收窄17.07%。此外，公司在TCE（T细胞衔接器）等创新药技术平台上的进展也受到关注，其基于空间位阻介导的双抗和三抗开发技术具有潜在优势，增强了投资者对公司研发管线未来潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557899","title":"迈威生物（688062）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557899?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:52","pubTimestamp":1777503142,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2026年一季报。根据财报显示，迈威生物营收上升亏损收窄。截至本报告期末，公司营业总收入1.28亿元，同比上升184.89%，归母净利润-2.42亿元，同比上升17.07%。本次财报公布的各项数据指标表现尚佳。持有迈威生物最多的基金为易方达医药生物股票A，目前规模为19.96亿元，最新净值0.8025，较上一交易日下跌0.86%，近一年上涨13.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184757618","title":"异动解读 | 迈威生物-B盘中大跌5.11%，一季度净亏损2.42亿元拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1184757618","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184757618?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:55","pubTimestamp":1777434903,"startTime":"0","endTime":"0","summary":"迈威生物-B（02493）今日盘中大跌5.11%，引发了市场的广泛关注。消息面上，公司于盘前发布了2026年第一季度财务报告。报告显示，公司期内归母净亏损为2.42亿元人民币，尽管亏损同比有所收窄，但整体业绩仍处于亏损状态。同时，公司资产负债率高达93.67%，较上一季度显著增加，凸显了其财务杠杆压力。这份不及市场预期的财报是导致股价承压下跌的主要原因。根据财报数据，迈威生物一季度营业收入为1.28亿元，同比增长显著。然而，高企的负债率以及持续的净亏损，削弱了投资者对公司短期盈利能力和财务健康状况的信心，从而在盘中引发了抛售。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551636","title":"【特约大V】邓声兴：港股累跌两日有反弹之势，关键企稳26000","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551636","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631551636?lang=zh_cn&edition=full","pubTime":"2026-04-29 10:18","pubTimestamp":1777429087,"startTime":"0","endTime":"0","summary":"大市全日成交2623亿元。软银在日本股价跌幅达一成。港股累跌两日有反弹之势，关键企稳26000。值得留意的是，利润弹性并非单靠锂价，期内来自联营公司SQM的投资收益约4.28亿元，按年大增，加上财务费用由正转负至-1.51亿元，以及资产减值净转回约1.14亿元，多项因素共同放大盈利弹性，最终营业利润达37.36亿元。惟SQM与Codelco合作交易正式生效，天齐智利在当地诉讼终审败诉，公司表明将动态评估该长期股权投资的价值变动。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980185","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1227","BK1161","BK4585","09696","SG9999014674.SGD","BK1500","VXUS","02493","BK1512","01879","BK1129","01361","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134346291","title":"迈威生物-B2026年第一季度营收1.28亿元，经调整净利润-2.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134346291","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134346291?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:46","pubTimestamp":1777387601,"startTime":"0","endTime":"0","summary":"2026年第一季度，迈威生物-B实现营收1.28亿元，同比增加184.89%。根据公告列示的扣除非经常性损益后净利润为-2.42亿元。报告期内，经营活动产生的现金流量净额为-2.34亿元。公司在研发方面继续加大投入，第一季度研发费用为1.64亿元，占营收比重达到128.92%，同比下降21.12%，主要原因在于本期营业收入大幅增长。销售费用为0.69亿元，管理费用为0.61亿元。（以上数据信息均来自迈威生物-B于2026年4月28日发布的第一季度财报，仅供参考。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"迈威生物-B2026年第一季度营收1.28亿元，经调整净利润-2.42亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630025983","title":"迈威生物2026年第一季度净亏损2.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630025983","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630025983?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:24","pubTimestamp":1777379083,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩宋雨盈）4月28日，迈威生物发布2026年第一季度报告，报告期内，公司实现营业收入1.28亿元，同比增长184.89%；归属于上市公司股东的净亏损为2.42亿元，上年同期为亏损2.92亿元；归属于上市公司股东的扣除非经常性损益的净亏损为2.42亿元，上年同期为亏损2.93亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283722717414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722717414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167722309","title":"异动解读 | 迈威生物-B H股上市首日盘中大涨5.21%，获超高认购及调入港股通提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1167722309","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167722309?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:38","pubTimestamp":1777340310,"startTime":"0","endTime":"0","summary":"迈威生物-B（02493）今日盘中股价大幅上涨5.21%，表现强劲。消息面上，公司H股于今日在香港联交所主板正式挂牌上市。根据配发结果，其香港公开发售获得481.71倍的大幅超额认购，显示出市场极高的认购热情。同时，深交所发布公告，自今日起将迈威生物-B调入深港通下的港股通标的证券名单，这意味着该股将获得内地投资者的直接参与，有望提升其市场流动性和关注度。迈威生物-B是一家专注于ADC与TCE等前沿肿瘤治疗领域的创新药企，已有产品实现商业化。此次成功登陆港股市场并获得资金追捧，叠加被纳入港股通的投资便利，共同构成了今日股价上涨的主要驱动力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07bac0175d858e54df48541d68aa044c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102446045","title":"深港通下的港股通标的证券名单调入迈威生物-B，今日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1102446045","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102446045?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:43","pubTimestamp":1777337012,"startTime":"0","endTime":"0","summary":"深交所公告，港股通标的证券名单发生调整并自2026年04月28日起生效，调入迈威生物-B。","market":"us","thumbnail":"https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07bac0175d858e54df48541d68aa044c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115348293","title":"新股定价 | 迈威生物下限定价，公开发售超购480.71倍，一手中签率1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115348293","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115348293?lang=zh_cn&edition=full","pubTime":"2026-04-28 07:59","pubTimestamp":1777334351,"startTime":"0","endTime":"0","summary":"$迈威生物-B$ 公布招股结果，香港公开发售接获481.71倍认购，一手中签率1%，认购7万股稳获一手。国际发售录得3.46倍认购。最终发售价27.64港元，下限定价，集资净额11.89亿港元。股份预期今日挂牌。中国制药公司迈威生物本次拟全球发售4,713.02万股，公开发售占10%。招股价介乎27.64至30.71元。君实香港、Sanjin International、国惠香港、昌荣国际、WuXi Biologics Venture及中和资本等6名基石投资者共合认购1,502.06万股，占发售总数31.87%。禁售承诺最后一天2026年10月27日。","market":"hk","thumbnail":"https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07bac0175d858e54df48541d68aa044c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股定价 | 迈威生物下限定价，公开发售超购480.71倍，一手中签率1%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031601","title":"【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031601","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630031601?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:03","pubTimestamp":1777309406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 迈威生物-Ｂ 刊发全球发售配发结果公告，最终发售价厘定为每股27.64港元，股份将于2026年4月28日于港交所主板挂牌上市，每手买卖单位为200股。本次全球发售合共4713.02万股H股，其中香港公开发售4,713,200股，占全球发售10%；国际发售42,417,000股，占比90%。香港公开发售获大幅超额认购，有效申请126,378份，认购倍数约481.71倍，一手中签率为1.00%。国际发售获适度超额认购，认购倍数约3.46倍，承配人共82名。本次IPO未授出超额配售选择权。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","688062","02493","BK0239","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159873615","title":"迈威生物-B香港公开发售获481倍认购、集资约13.03亿元 将于4月28日挂牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1159873615","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159873615?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:11","pubTimestamp":1777299062,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司公布招股结果并确定 H 股最终发售价为每股27.64港元，为招股价区间下限。公司共发行47,130,200股 H 股，募资总额约13.03亿元，扣除约1.14亿元的预计上市开支后，所得款项净额约11.89亿元。H 股将于2026年4月28日（星期二）在香港联交所主板挂牌，买卖单位为每手200股。本次公开发售并未触发回拨及重新分配机制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630394291","title":"上交所：将迈威生物-B(02493)调入沪港通下的港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2630394291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630394291?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:09","pubTimestamp":1777295366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日，上海证券交易所发布关于沪港通下港股通标的调整的通知。因上海证券交易所上市公司迈威生物(688062.SH)在香港联合交易所有限公司上市H股迈威生物-B(02493)，其H股不适用价格稳定期机制，且相应A股上市满10个交易日，根据《上海证券交易所沪港通业务实施办法》的有关规定，沪港通下港股通(以下简称港股通)标的名单发生调整，调入迈威生物-B(02493)，并自下一港股通交易日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","BK4585","688062","BK4588","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629885897","title":"迈威生物（688062）披露2025年年度股东会增加香港会议地址公告，4月23日股价下跌5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629885897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629885897?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:22","pubTimestamp":1776954142,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，迈威生物报收于38.1元，较前一交易日下跌5.44%，最新总市值为152.25亿元。该股当日开盘40.25元，最高40.25元，最低37.41元，成交额达4.17亿元，换手率为5.33%。近日，迈威（上海）生物科技股份有限公司发布《关于2025年年度股东会增加会议地址的公告》。会议审议事项包括2025年年度报告、利润分配方案、续聘审计机构等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300062524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":-0.0716},{"period":"1month","weight":-0.0904},{"period":"ytd","weight":-0.0904}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0284},{"period":"3month","weight":-0.0238},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1419},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}